Posted inClinical Updates Wellness & Lifestyle
No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial
The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.